Next-generation anthracycline for the management of small cell lung cancer: Focus on amrubicin

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 189-192

  Yamamoto, Michiko ^a   Takakura, Akira ^a   Masuda, Noriyuki ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amrubicin; Anthracycline; Extensive disease; Small cell lung cancer

Indexed keywords

AMRUBICIN; AMRUBICINOL; CISPLATIN; DAUNOSAMINE; DOXORUBICIN; DRUG METABOLITE; TOPOTECAN; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG STRUCTURE; FEBRILE NEUTROPENIA; HUMAN; JAPAN; LUNG SMALL CELL CANCER; MONOTHERAPY; NEUTROPENIA; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTOPENIA;

EID: 77953678077     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Ettinger DS, Jotte RM, Gupta V, et al. 2008. A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) taht is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy. 44th Am Soc Clin Oncol Annual Meeting, Grunberg SM (ed), Vol.26. pp. 434a: Chicago.
2. Hanada M, Mizuno S, Fukushima A, et al. 1998. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res, 89:1229-1238 (Pubitemid 29008005)
3. Hira A, Watanabe H, Maeda Y, et al. 2008. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells. Biochem Pharmacol, 75:973-980 (Pubitemid 351174119)
4. Ishizumi K, Ohashi N, Tanno N, et al. 1987. Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem, 52:4477-4485 (Pubitemid 18061289)
5. Jotte RM, Conkling PR, Reynolds C, et al. 2008. A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. 44th Am Soc Clin Oncol Annual Meeting, Grunberg SM (ed), Vol.26. pp. 433a: Chicago.
6. Morisada S, Yanagi Y, Noguchi T, et al. 1989. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res, 80:69-76. (Pubitemid 20027201)
7. Noda T, Watanabe T, Kohda A, et al. 1998. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs, 16:121-128 (Pubitemid 28495213)
8. Noguchi T, Ichii S, Morisada S, et al. 1998. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res, 89:1055-1060 (Pubitemid 28544782)
9. Ohe Y, Negoro S, Matsui K, et al. 2005. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol, 16:430-436 (Pubitemid 40458320)
10. Onoda S, Masuda N, Seto T, et al. 2006. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol, 24:5448-5453 (Pubitemid 46623179)
11. Sher T, Dy GK, Adjei AA. 2008. Small cell lung cancer. Mayo Clin Proc, 83:355-367
12. Suzuki T, Minamide S, Iwasaki T, et al. 1997. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs, 15:219-225 (Pubitemid 27453876)
13. Takara K, Sakaeda T, Yagami T, et al. 2002. Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull, 25:771-778 (Pubitemid 40036714)
14. Yamaoka T, Hanada M, Ichii S, et al. 1998. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res, 89:1067-1073 (Pubitemid 28544784)
15. Yana T, Negoro S, Takada M, et al. 2007. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs, 25:253-258 (Pubitemid 46774694)